There are 304 resources available
Yes
Presenter: Francois Ghiringhelli
Session: Is TMB a good predictive biomarker for immunotherapy?
Resources:
Slides
Webcast
119O - Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study
Presenter: Martin Wermke
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Lessons learned from combination immunotherapy in melanoma
Presenter: John Haanen
Session: Collaborative session ESMO-SITC
Resources:
Slides
Webcast
Invited Discussant 119O
Presenter: Anna Di Giacomo
Session: Proffered Paper session 2
Resources:
Slides
Webcast
No
Presenter: Benoit Rousseau
Session: Is TMB a good predictive biomarker for immunotherapy?
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Collaborative session ESMO-SITC
Resources:
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2
Resources:
Webcast
Second vote and conclusions
Presenter: Aurelien Marabelle
Session: Is TMB a good predictive biomarker for immunotherapy?
Resources:
Slides
Webcast
Lessons learned from combination immunotherapy in GU cancers
Presenter: Mathieu Rouanne
Session: Collaborative session ESMO-SITC
Resources:
Slides
Webcast
48O - Safety and Efficacy of Combined Treatment with Tumor Infiltrating Lymphocytes (TILs) and Oncolytic Adenovirus TILT-123 for Patients with Metastatic Melanoma - Results from a Phase I Trial
Presenter: Tine Monberg
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast